C4 Therapeutics (CCCC) Change in Receivables (2019 - 2026)

C4 Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at $482000.0 for Q1 2026.

• On a quarterly basis, Change in Receivables fell 90.22% year-over-year to $482000.0 in Q1 2026; TTM through Mar 2026 was -$5.1 million, a 7.63% increase from a year earlier, with the FY2025 full-year figure at -$701000.0, up 91.94% from the prior year.
• Change in Receivables advanced to $482000.0 in Q1 2026 per CCCC's latest filing, from -$4.1 million in the prior quarter.
• Across five years, Change in Receivables topped out at $11.3 million in Q4 2023 and bottomed at -$12.4 million in Q2 2024.
• The 5-year median for Change in Receivables is -$63000.0 (2022), against an average of -$166647.1.
• Across the five-year window, Change in Receivables surged 75433.33% in 2023 and sank 2586.2% in 2024, its largest moves.
• Year by year, Change in Receivables stood at -$15000.0 in 2022, then jumped by 75433.33% to $11.3 million in 2023, then slumped by 164.06% to -$7.2 million in 2024, then surged by 42.8% to -$4.1 million in 2025, then soared by 111.64% to $482000.0 in 2026.
• Per Business Quant, the three latest CCCC Change in Receivables figures stand at $482000.0 (Q1 2026), -$4.1 million (Q4 2025), and $4.3 million (Q3 2025).